Shield Diagnostics Group, plc
This article was originally published in The Gray Sheet
Executive Summary
Raises about $3.8 mil., net of expenses, in private placement of 499,361 new ordinary shares with institutional investors. Proceeds are tabbed for further commercialization of the Dundee, UK firm's Afecta (Activated Factor XII) and homocysteine cardiovascular tests, "including the development of new point-of-care diagnostics," the company states. The placement was arranged by Nomura International, plc
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.